Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiM™) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes.

Part I of Arrowhead’s 2026 Summer Series of R&D Webinars will focus on Arrowhead’s cardiometabolic pipeline and will be held on June 29, 2026, at 11:30 AM EDT. The webinar will feature a presentation from Steven Nissen, M.D., Chief Academic Officer for the Heart and Vascular Institute at the Cleveland Clinic, the Lewis and Patricia Dickey Chair in Cardiovascular Medicine and Professor of Medicine at the Lerner College of Medicine. The webinar will also feature presentations from Arrowhead management.

The agenda for Part I – Cardiometabolic is listed below: